Cargando…

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

ATR and ATM are DNA damage signaling kinases that phosphorylate several thousand substrates. ATR kinase activity is increased at damaged replication forks and resected DNA double-strand breaks (DSBs). ATM kinase activity is increased at DSBs. ATM has been widely studied since ataxia telangiectasia i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vendetti, Frank P., Lau, Alan, Schamus, Sandra, Conrads, Thomas P., O'Connor, Mark J., Bakkenist, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792557/ https://www.ncbi.nlm.nih.gov/pubmed/26517239

Ejemplares similares

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
por: Vendetti, Frank P., et al.
Publicado: (2023)

Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice
por: Kiesel, Brian F., et al.
Publicado: (2022)

The Application of ATR Kinase Inhibitor AZD6738 in Combination with Radiotherapy for the Treatment of Melanoma
por: Talebpoor, Maryam, et al.
Publicado: (2022)

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation
por: Vendetti, Frank P., et al.
Publicado: (2017)

ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1
por: Moiseeva, Tatiana, et al.
Publicado: (2017)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2015)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5-fluorouracil by inhibiting repair of DNA damage
por: Suzuki, Takuya, et al.
Publicado: (2022)

Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma: ATM, ATR and FA in lung carcinoma
por: Beumer, Jan H., et al.
Publicado: (2015)

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
por: Sheng, Hailong, et al.
Publicado: (2020)

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
por: O'Flanagan, Ciara H., et al.
Publicado: (2016)

AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
por: Harata, Shinnosuke, et al.
Publicado: (2023)

ATM protein is deficient in over 40% of lung adenocarcinomas
por: Villaruz, Liza C., et al.
Publicado: (2016)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression
por: Sugitani, Norie, et al.
Publicado: (2022)

An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
por: Huang, Longxiang, et al.
Publicado: (2022)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

ATM, ATR and DNA-PKcs kinases—the lessons from the mouse models: inhibition ≠ deletion
por: Menolfi, Demis, et al.
Publicado: (2020)

The Telomeric Protein TRF2 Binds the ATM Kinase and Can Inhibit the ATM-Dependent DNA Damage Response
por: Karlseder, Jan, et al.
Publicado: (2004)

The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation
por: Fan, Guangjian, et al.
Publicado: (2021)

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
por: Dillon, M.T., et al.
Publicado: (2018)

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
por: Lloyd, Rebecca L., et al.
Publicado: (2020)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
por: Davis, S. Lindsey, et al.
Publicado: (2022)

"ATR activation in response to ionizing radiation: still ATM territory"
por: Cuadrado, Myriam, et al.
Publicado: (2006)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)
por: Ring, Alistair, et al.
Publicado: (2023)

WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
por: Moiseeva, Tatiana N., et al.
Publicado: (2019)

Cleavage of Cdc6 by caspase-3 promotes ATM/ATR kinase–mediated apoptosis of HeLa cells
por: Yim, Hyungshin, et al.
Publicado: (2006)

ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage
por: Gamper, Armin M., et al.
Publicado: (2013)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Ataxia-televangelist mutated (ATM)/ ATR serine/threonine kinase (ATR)-mediated RAD51 recombinase (RAD51) promotes osteogenic differentiation and inhibits osteoclastogenesis in osteoporosis
por: Qiu, Minli, et al.
Publicado: (2022)

Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice
por: Yamamoto, Kenta, et al.
Publicado: (2012)

ATR Contributes More Than ATM in Intra-S-Phase Checkpoint Activation after IR, and DNA-PKcs Facilitates Recovery: Evidence for Modular Integration of ATM/ATR/DNA-PKcs Functions
por: Soni, Aashish, et al.
Publicado: (2022)

The Dimeric Architecture of Checkpoint Kinases Mec1(ATR) and Tel1(ATM) Reveal a Common Structural Organization
por: Sawicka, Marta, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3rg7igecbrvb2c1g38aqcmhlng